Harnessing the power of the endocannabinoid system.

Our goal is to become a global leader in the development of safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions. OCT's primary focus is on the drug development for indications in severe, chronic pain conditions, that are one of the biggest challenges facing society today.


Find out more

Our Approach

OCT utilises a range of compounds in drug development, including proprietary cannabinoid derivatives, natural phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, long-term market value, and market exclusivity across all activities.


Find out more

Meet the Team

With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCT's team is committed to excellence. Together, we are passionate about delivering breakthrough therapies for life-threatening conditions with a significant unmet medical need.


Find out more

Recent news, reports & resources


All News

  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update

Get in touch

Oxford Cannabinoid Technologies Ltd
1 Maddox Street
London W1S 2PZ

Find us on a map